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Abstract 
A recent observational study of HIV patients in Germany suggests that treatment naïve patients that are in a more 
advanced stage of their disease are more likely to receive a treatment regimen based on a boosted protease inhibitor 
(PI/r) compared with a non-nucleoside reverse-transcriptase-inhibitor (NNRTI) base regimen. To validate those results 
we analysed claims data of seven German sickness funds from 2009 to 2012 with approximately 4 million beneficiar-
ies. Patients in a more advanced disease state (CDC class C) had a higher likelihood to receive a PI/r based regime 
rather than a NNRTI based regimen as their initial treatment. There was also a significant correlation between PI/r 
based regimen and number of comorbidities but not with age. Our results confirm a highly significant relationship 
between being in a more severe stage of HIV disease and a PI/r based treatment regimen.
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Background
A recent analysis of a German cohort of human immu-
nodeficiency virus (HIV) infected patients revealed that 
the choice of the treatment regimen for the initiation of 
antiretroviral therapy is not random. Rather, the results of 
the study suggest that patients that are in a more severe 
stage in HIV do more likely receive a boosted protease 
inhibitor (PI/r) based treatment regimen compared with a 
non-nucleoside reverse-transcriptase-inhibitor (NNRTI) 
based regimen (Mahlich et al. 2015). The rationale for this 
treatment decision can be seen in the different resistance 
barriers of the two drug classes. Previous research found 
that impaired adherence has a bigger impact on treat-
ment failure in NNRTI-based as compared to PI/r-based 
treatment strategies (Parienti et  al. 2010; Rosenbloom 
et al. 2012). To avoid antiretroviral resistance and subse-
quent virological failure, patients that are believed to take 
their medication only irregularly would preferably receive 
a PI/r based regimen, while patients with a potentially 
good adherence may receive a NNRTI based regimen. 
The obvious question is then, how physicians can identify 
patient’s future adherence a priory. Some determinants 
of adherence have been identified in the literature that 
might provide some guidance to the physician. Identified 
factors that negatively influence adherence include lower 
age (Hinkin et  al. 2004), lower income (Carballo et  al. 
2004), concomitant diseases (Shah et al. 2007), as well as 
disease specific factors such as an advanced disease stage 
(Protopopescu et al. 2009). Using the CDC classification 
system for HIV-infection (Centers for Disease Control 
and Prevention 1992), the German observational study 
mentioned before (Mahlich et al. 2015) established a rela-
tionship between the likelihood of PI/r prescription and 
CDC status C which indicates the worst disease status 
(CDC status A on the other hand would indicate the mild-
est form of the disease). The goal of this study is to vali-
date the findings of the observational study with German 
claims data. Permission was granted to access the data 
and the analysis was carried out according to the guide-
lines of all institutions involved.
Methods
We analysed claims data of seven German sickness funds 
from 2009 to 2012 with approximately 4 million insurants. 
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5,792 or 0.14% of them were found to be diagnosed with 
HIV, we refer to them as ‘people living with HIV or AIDS’ 
(PLWHA). Only 35.6% of the diagnosed patients receive 
antiretroviral treatment of which 21.2% were identified as 
being on their first treatment regimen (Table 1). The low 
treatment rate can be attributed to coding errors that have 
inflated the number of HIV diagnoses in Germany during 
our observation period (Tomeczkowski et al. 2015). As we 
only consider patients under treatment, our analysis is not 
affected by this bias. A patient was defined to be on first 
line treatment regimen when she has received no prior 
treatment. The minimum observation period to deter-
mine the treatment status was 6 month. That is to say that 
in order to qualify for the treatment naïve status a patient 
was at least for 6 month without antiretroviral prescrip-
tions. Applying this definition we might have incorrectly 
defined a treatment experienced patient as being treat-
ment naïve when this patient is on a treatment break of 
more than 6  month. As treatment breaks are not rec-
ommended in any guidelines we do not believe that this 
source of a potential bias is significant.
The disease stage according to the CDC classification 
system is not recorded in the claims database. To test 
the proposition that the treatment regimen is related to 
the disease stage, we therefore had to construct the CDC 
classification based on co-morbidities. CDC stage defin-
ing co-morbidities can be found in a publication of the 
U.S. Department of Health and Human Services (2014) 
and are reported in the “Appendix”.
We then analyse if the distribution of patients in dis-
ease stage CDC C differs across the two treatment strat-
egies (PI/r and NNRTI based regimen). To check the 
significance of any observed difference we apply a Chi 
squared test. The p value <0.5 (two sided) was considered 
as being statistically significant.
We also compare our result with that of Mahlich et al. 
(2015) which is based on observational data. We are able 
to make this comparison also with regards to two other 
patient characteristics, namely ‘age’ and having ‘three or 
more concomitant diseases’.
Results
The result of our analysis is displayed in Figure  1 that 
shows the proportion of treatment naïve CDC C patients 
according to the drug class. It can be seen from the 
chart that 37.4% of the treatment naïve PI/r patients are 
in CDC stage C while this fraction is only 23.4% for the 
patients receiving a NNRTI based treatment regimen. 
The Chi squared test takes the value 15.224 and the asso-
ciated p value is <0.001. The observed difference is there-
fore highly significant.
In Table  2 the results with regard to ‘age’ and ‘three or 
more concomitant disease’ are compared with those of 
Mahlich et al. (2015). With regard to age we found no sig-
nificant difference between NNRTI and PI/r patients (p 
value 0.139) which is also the result reported by the Ger-
man observational study. On the other hand we found a sig-
nificant difference with regard to the presence of more than 
Table 1 Description of the sample
Number of patients (%)
Total sick fund population 4,000,000 (100)
HIV diagnosed Total PLWHA 5,792 (0.14)
ART Total ART 2,082 (35.95)




Figure 1 Share of treatment naïve patients in CDC C stage according to treatment regimen.
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concomitant diseases. Only 27.6% of NNRTI patients had 
three or more concomitant diseases, while this fraction was 
37.1% for PI/r patients. The difference was statistically sig-
nificant as well (p value 0.050), implying that multi morbid 
patients are more likely to receive a PI/r based treatment.
Discussion
The results presented in this paper confirm that physi-
cians´ treatment decision towards a PI/r based treat-
ment strategy for the initiation of antiretroviral treatment 
in therapy naïve HIV patients is influenced by a more 
advanced disease stage of HIV-infection. Contrary to the 
results of the German observational study we also found 
the number of concomitant diseases significantly related 
to a PI/r based treatment regimen. Despite today’s effec-
tive and available antiretroviral treatment, a significant 
proportion of PLWHA are still diagnosed as late present-
ers in progressed disease stages. This particular subgroup 
is characterized by a worse outcome and causes higher 
costs to the health care system. Both health policy deci-
sion makers and physicians should certainly consider 
improved strategies to address individuals with high risk 
to prevent late presentation.
To our knowledge this analysis investigating param-
eters that drive the treatment decision between NNRTI 
and PI/r based regimens for the initiation of antiretrovi-
ral therapy is the first study using claims data. So far this 
research question has only be analysed in the context of 
observational studies, be it in the UK (Easterbrook et al. 
2008), Switzerland (Elzi et al. 2012) or Germany (Mahl-
ich et al. 2015). The results also highlight the opportuni-
ties that arise with the utilization of claims data which are 
increasingly easy to access.
Conclusions
The German claims data analysis confirms that the treat-
ment decision for NNRTI or PI/r based regimen is asso-
ciated with the disease severity. The result is in line with 
results from observational studies.
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 Patient age (in years) at diagnosis
  <50 62.8 8.3 67.2 89.5
  ≥50 37.2 21.7 32.8 10.5
Anamnestic factors
 HIV stage according to CDC-classification
  A + B 76.6 89.1 62.9 63.2
  C (aids) 23.4 10.9 37.1 36.8
 Three or more concomitant diseases
  No 72.7 80.4 62.9 76.3
  Yes 27.6 19.6 37.1 23.7
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Vulvovaginal candida infections, which are either chronic (longer than 
1 month) or only poorly treatable
Cervical dysplasia or carcinoma in situ
Constitutional symptoms such as fever above 38.5°C or more than 
4 weeks existing diarrhea
Oral hairy leukoplakia










Oesophageal candida infection or infection of the bronchi, trachea or 
lungs
Chronic herpes simplex or herpes ulcers bronchitis, pneumonia or 
esophagitis
CMV retinitis
Generalized CMV infection (not liver or spleen)
Recurrent Salmonella septicemia
Recurrent pneumonias within one year
Extrapulmonary cryptococcal infections
Chronic intestinal cryptosporidiosis infection
Chronic intestinal infection with Isospora belli
Disseminated histoplasmosis or extrapulmonary
Tuberculosis
Infections with mycobacterium avium complex or M. kansasii, dissemi-
nated or extrapulmonary
Kaposi’s sarcoma
Malignant lymphomas (Burkitt, immunoblastic or primary cerebral 
lymphoma)
Invasive cervical carcinoma
HIV encephalopathy
Progressive multifocal leukoencephalopathy
Wasting syndrome
